Neutral sphingomyelinase (Smpd3), encoding for nSMase2, was recently identified as an FXR target gene mediating the effects on intestinal ceramide (mainly C16:0) production and secretion, also in the pathophysiology of atherosclerosis [222]. Here, SMPD3 is linked to atherosclerosis.